# Nasus Pharma Ltd. (NSRX)

Source: https://www.quantisnow.com/company/NSRX
Generated: 2026-11-17T19:29:32.580Z

- Ticker: NSRX
- Exchange: AMEX
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2025
- SEC CIK: 0002029039

## Latest NSRX news and filings

- 2026-11-17 13:00 UTC [Nasus Pharma Presents Data at ACAAI 2026 Demonstrating NS002 Reached the Therapeutic Epinephrine Threshold Faster Than an Autoinjector After Repeat Dosing and Under Severe Nasal Congestion](https://www.quantisnow.com/insight/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-6795798)
- 2026-11-16 21:06 UTC [SEC Form 4] [SEC Form 4 filed by Interim CFO Elmaliah Oren](https://www.quantisnow.com/insight/sec-form-4-filed-by-interim-cfo-elmaliah-oren-6794033)
- 2026-11-16 13:20 UTC [SEC Form 6-K] [SEC Form 6-K filed by Nasus Pharma Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nasus-pharma-ltd-6792524)
- 2026-11-16 13:00 UTC [Leadership Update] [Nasus Pharma Appoints Nir Sassi as Chief Financial Officer](https://www.quantisnow.com/insight/nasus-pharma-appoints-nir-sassi-as-chief-financial-officer-6792329)
- 2026-11-16 11:07 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by Nasus Pharma Ltd.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-nasus-pharma-ltd-6792007)
- 2026-11-14 00:35 UTC [SEC Form 4] [Chief Executive Officer O'Grady Brendan P. was granted 210,000 share options (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-ogrady-brendan-p-was-granted-210000-share-6791728)
- 2026-11-10 13:00 UTC [Nasus Pharma Announces Abstracts Accepted for Presentation at ACAAI 2026](https://www.quantisnow.com/insight/nasus-pharma-announces-abstracts-accepted-for-presentation-at-acaai-2026-6782975)
- 2026-10-19 20:50 UTC [SEC Form S-8] [SEC Form S-8 filed by Nasus Pharma Ltd.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-nasus-pharma-ltd-6750892)
- 2026-10-08 20:30 UTC [SEC Form 6-K] [SEC Form 6-K filed by Nasus Pharma Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nasus-pharma-ltd-6741913)
- 2026-09-29 12:00 UTC [Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron](https://www.quantisnow.com/insight/nasus-pharma-announces-enrollment-and-dosing-of-first-patient-in-6728424)
- 2026-09-23 10:14 UTC [SEC Form 3] [SEC Form 3 filed by new insider Elmaliah Oren](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-elmaliah-oren-6723524)
- 2026-09-21 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Chief Financial Officer Rubin Eyal](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-financial-officer-rubin-eyal-6721615)
- 2026-09-18 20:43 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Nasus Pharma Ltd.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-nasus-pharma-ltd-6720719)
- 2026-09-18 20:06 UTC [SEC Form 6-K] [SEC Form 6-K filed by Nasus Pharma Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nasus-pharma-ltd-6720492)
- 2026-09-14 12:15 UTC [SEC Form 6-K] [SEC Form 6-K filed by Nasus Pharma Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nasus-pharma-ltd-6713845)
- 2026-09-14 12:00 UTC [Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis](https://www.quantisnow.com/insight/nasus-pharma-announces-fda-clearance-to-initiate-clinical-study-of-6713763)
- 2026-09-14 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Nasus Pharma Ltd.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-nasus-pharma-ltd-6713545)
- 2026-09-08 11:30 UTC [Conference Announcement] [Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference](https://www.quantisnow.com/insight/nasus-pharma-to-participate-in-the-hc-wainwright-28th-annual-6707443)
- 2026-09-04 20:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by Nasus Pharma Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nasus-pharma-ltd-6706728)
- 2026-09-01 20:51 UTC [SEC Form F-3 filed by Nasus Pharma Ltd.](https://www.quantisnow.com/insight/sec-form-f-3-filed-by-nasus-pharma-ltd-6701685)
- 2026-08-21 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Nasus Pharma Ltd.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-nasus-pharma-ltd-6690691)
- 2026-08-19 13:21 UTC [SEC Form 6-K] [SEC Form 6-K filed by Nasus Pharma Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nasus-pharma-ltd-6688013)
- 2026-08-19 11:00 UTC [Nasus Pharma Announces Transition of Chief Financial Officer](https://www.quantisnow.com/insight/nasus-pharma-announces-transition-of-chief-financial-officer-6687706)
- 2026-08-17 12:40 UTC [SEC Form 6-K] [SEC Form 6-K filed by Nasus Pharma Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nasus-pharma-ltd-6684488)
- 2026-08-17 12:14 UTC [Earnings] [Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/nasus-pharma-reports-first-half-2026-financial-results-and-provides-6684359)
- 2026-08-14 10:06 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Nasus Pharma Ltd.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-nasus-pharma-ltd-6681691)
- 2026-07-31 20:25 UTC [SEC Form 3] [SEC Form 3 filed by new insider O'Grady Brendan P.](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-ogrady-brendan-p-6657961)
- 2026-07-29 21:00 UTC [SEC Form 4] [SEC Form 4 filed by Chief Executive Officer Teleman Dan Benjamin](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-executive-officer-teleman-dan-6654220)
- 2026-07-28 12:34 UTC [SEC Form 6-K] [SEC Form 6-K filed by Nasus Pharma Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nasus-pharma-ltd-6650855)
- 2026-07-28 11:30 UTC [Leadership Update] [Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth](https://www.quantisnow.com/insight/nasus-pharma-appoints-pharmaceutical-industry-veteran-brendan-p-ogrady-as-6650616)
- 2026-06-26 12:35 UTC [Conference Announcement] [Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing](https://www.quantisnow.com/insight/life-sciences-virtual-investor-forum-presentations-now-available-for-on-demand-6616806)
- 2026-06-23 12:35 UTC [Conference Announcement] [Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th](https://www.quantisnow.com/insight/life-sciences-virtual-investor-forum-agenda-announced-for-june-24th-6612016)
- 2026-06-22 12:00 UTC [Conference Announcement] [Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum](https://www.quantisnow.com/insight/nasus-pharma-to-participate-in-the-zacks-life-sciences-investor-6610066)
- 2026-06-22 11:12 UTC [Insider Buy] [Chief Executive Officer Teleman Dan Benjamin bought $20,305 worth of Ordinary Shares (6,550 units at $3.10), increasing direct ownership by 4% to 163,541 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-teleman-dan-benjamin-bought-20305-worth-of-6609961)
- 2026-06-09 20:06 UTC [SEC Form 6-K] [SEC Form 6-K filed by Nasus Pharma Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nasus-pharma-ltd-6595241)
- 2026-06-09 12:00 UTC [Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)](https://www.quantisnow.com/insight/nasus-pharma-announces-positive-results-from-preclinical-pharmacokinetic-and-safety-6594567)
- 2026-06-01 12:00 UTC [Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis](https://www.quantisnow.com/insight/nasus-pharma-to-host-virtual-kol-event-on-june-10-6580715)
- 2026-05-26 21:20 UTC [SEC Form S-8] [SEC Form S-8 filed by Nasus Pharma Ltd.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-nasus-pharma-ltd-6573016)
- 2026-05-15 10:12 UTC [SEC Form SCHEDULE 13G filed by Nasus Pharma Ltd.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-nasus-pharma-ltd-6555433)
- 2026-05-01 13:13 UTC [Conference Announcement] [Nasus Pharma to Participate in Upcoming Investor Conferences](https://www.quantisnow.com/insight/nasus-pharma-to-participate-in-upcoming-investor-conferences-6526084)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/NSRX
- Earnings history: https://www.quantisnow.com/earnings/NSRX
- Dividend history: https://www.quantisnow.com/dividends/NSRX
- Insider transactions: https://www.quantisnow.com/insiders/NSRX
- Options chain: https://www.quantisnow.com/options/NSRX
- SEC 8-K filings only: https://www.quantisnow.com/company/NSRX/8-k
- RSS and alerts for NSRX: https://www.quantisnow.com/docs/rss-feeds.md
